Tinnitus vs Migraine — Clinical Trial Comparison
Tinnitus
Ringing or sounds without external source
Migraine
Severe headache with neurological symptoms
Tinnitus and migraine are both neurological conditions involving altered sensory processing. They frequently co-occur — migraine patients have a higher rate of tinnitus, and vice versa — and both share mechanisms of central sensitisation and neural hyperexcitability. Their trial landscapes are very different, with migraine benefiting from a wave of CGRP-targeted drugs while tinnitus trials focus on neuromodulation and sound-based therapies.
Key Differences at a Glance
| Feature | Tinnitus | Migraine |
|---|---|---|
| Primary symptom | Perception of sound without external source (ringing, buzzing, humming, pulsing) | Severe throbbing headache, often one-sided, with nausea, light/sound sensitivity |
| UK prevalence | ~10–15% of adults (~6–7 million) | ~15–20% of adults (~10 million) |
| Types | Subjective (most common), objective, pulsatile, somatic | Episodic, chronic (≥15 days/month), migraine with/without aura, vestibular |
| Disability impact | Sleep disturbance, concentration difficulty, anxiety, depression in severe cases | Debilitating attacks lasting 4–72 hours, ranked #2 cause of global disability |
| Approved drug treatments | None specifically approved for tinnitus | Triptans, CGRP antibodies, gepants, ditans, anti-epileptics, beta-blockers |
| Co-occurrence | ~25–30% of tinnitus patients have migraine history | ~30–40% of migraine patients report tinnitus |
Clinical Trial Availability
| Trial Aspect | Tinnitus | Migraine |
|---|---|---|
| UK trials actively recruiting | 10–20 studies | 40–60 studies |
| Most common trial phase | Phase 1–2 (early-stage field) | Phase 2–4 (mature field) |
| Top interventions tested | Sound therapy, neuromodulation, NMDA antagonists, hearing aids, CBT-based approaches | CGRP inhibitors (new formulations), gepants, neuromodulation devices, anti-CGRP antibodies |
| Drug trials | Few — no proven pharmacological approach yet | Many — largest category |
| Device trials | Significant (tDCS, TMS, acoustic neuromodulation) | Growing (external vagus nerve stim, TMS, Cefaly) |
| Prevention trials | Limited (hearing protection, early intervention) | Major category (CGRP antibodies, lifestyle, supplements) |
Exciting Emerging Treatments
Tinnitus Trials
- Acoustic coordinated reset neuromodulation — targeted sound therapy to disrupt pathological neural synchrony
- Bimodal neuromodulation (Lenire) — combining sound and tongue stimulation, approved and in further trials
- NMDA receptor antagonists (AM-101) — intratympanic injection targeting cochlear hyperexcitability
- Transcranial direct current stimulation (tDCS) — non-invasive brain stimulation modulating auditory cortex
- Hearing aid-based sound therapy — next-generation devices with built-in tinnitus programmes
- Deep brain stimulation — for severe, treatment-resistant tinnitus
Migraine Trials
- Next-generation CGRP inhibitors — oral gepants for acute and preventive use (rimegepant, atogepant)
- Ditans (lasmiditan) — novel serotonin 5-HT1F receptor agonist without vasoconstriction
- Anti-CGRP antibodies — new formulations and longer-acting versions (fremanezumab, galcanezumab)
- External neuromodulation devices — non-invasive vagus nerve stimulation, TMS
- Pituitary adenylate cyclase-activating peptide (PACAP) inhibitors — new target beyond CGRP
- Digital therapeutics — app-based behavioural therapy for migraine prevention
💡 Have both tinnitus and migraine? Target the migraine first
Research shows that treating migraine can significantly improve tinnitus in patients with both conditions. This may be because migraine-related blood flow changes and neural sensitisation contribute to tinnitus. If you have both, several UK migraine trials may accept you — and improving one condition often helps the other. Ask your neurologist about combined treatment approaches.
Eligibility Differences
Tinnitus Trial Criteria
- Tinnitus duration requirement (typically ≥ 6 months for chronic tinnitus trials)
- Severity scoring (Tinnitus Handicap Inventory, Visual Analogue Scale thresholds)
- Hearing assessment — degree of hearing loss affects trial categorisation
- Subjective vs objective tinnitus distinction (most trials are for subjective)
- Exclusion of treatable causes (acoustic neuroma, vascular abnormalities)
Migraine Trial Criteria
- ICHD-3 migraine diagnosis required (with or without aura specified)
- Attack frequency requirements (e.g., 4–14 migraine days/month for preventive trials)
- Migraine diary data usually required for 1–3 months before enrolment
- Chronic migraine (≥15 days) vs episodic — separate trial categories
- Failed preventive treatments may be required for refractory migraine trials
🔔 Tinnitus Trials
Find actively recruiting tinnitus clinical trials across the UK
View Tinnitus Trials💫 Migraine Trials
Find actively recruiting migraine clinical trials across the UK
View Migraine Trials